A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration.

[1]  E. Souied,et al.  Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. , 2020, Ophthalmology.

[2]  J. Pearlman,et al.  Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration. , 2019, Ophthalmology. Retina.

[3]  K. Lashkari,et al.  Plasma Levels of VEGF-C and Soluble VEGF Receptor-3 are Elevated in Neovascular AMD , 2017 .

[4]  K. Alitalo,et al.  VEGFR3 Modulates Vascular Permeability by Controlling VEGF/VEGFR2 Signaling , 2017, Circulation research.

[5]  C Bunce,et al.  Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013 , 2016, Eye.

[6]  S. Harding,et al.  Defining response to anti-VEGF therapies in neovascular AMD , 2015, Eye.

[7]  Cizhong Jiang,et al.  Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. , 2014, Cancer letters.

[8]  A. Hafezi-Moghadam,et al.  Lack of lymphatics and lymph node-mediated immunity in choroidal neovascularization. , 2013, Investigative ophthalmology & visual science.

[9]  Christian Simader,et al.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.

[10]  B. Detrick,et al.  Regulation of VEGF expression in human retinal cells by cytokines: Implications for the role of inflammation in age‐related macular degeneration , 2012, Journal of cellular physiology.

[11]  J. Pollard,et al.  VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling , 2011, Nature Cell Biology.

[12]  Glenn J Jaffe,et al.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.

[13]  L. Ellis,et al.  Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration , 2011, British Journal of Cancer.

[14]  F. Winkler,et al.  Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells , 2011, Journal of Neuro-Oncology.

[15]  H. Kaplan,et al.  Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? , 2008, Ophthalmology.

[16]  A. Joussen,et al.  Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions , 2007, British Journal of Ophthalmology.

[17]  Philip J Rosenfeld,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[18]  Susan Schneider,et al.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.

[19]  Philip J Rosenfeld,et al.  Ranibizumab: Phase III clinical trial results. , 2006, Ophthalmology clinics of North America.

[20]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[21]  N. Schenker,et al.  On Judging the Significance of Differences by Examining the Overlap Between Confidence Intervals , 2001 .

[22]  M. Karkkainen,et al.  The Specificity of Receptor Binding by Vascular Endothelial Growth Factor-D Is Different in Mouse and Man* , 2001, The Journal of Biological Chemistry.

[23]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[24]  K. Alitalo,et al.  Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Isner,et al.  Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. , 1998, The American journal of pathology.

[26]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[27]  F. Ferris,et al.  New visual acuity charts for clinical research. , 1982, American journal of ophthalmology.

[28]  V. Mahajan,et al.  Bevacizumab Injection in Patients with Neovascular Age-Related Macular Degeneration Increases Angiogenic Biomarkers. , 2018, Ophthalmology. Retina.

[29]  M. Aghi,et al.  Mechanisms of evasion to antiangiogenic therapy in glioblastoma. , 2010, Clinical neurosurgery.

[30]  R. Dana,et al.  Growth Factors , Cytokines , Cell Cycle Molecules Contribution of Macrophages to Angiogenesis Induced by Vascular Endothelial Growth Factor Receptor-3-Specific Ligands , 2010 .